BEDFORD, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced results from two pivotal Phase 3 studies evaluating the diagnostic performance of the TAUKLARIFY™ (florquinitau F 18 injection) PET imaging, also referred to as MK-6240, which supported FDA use in adults with cognitive impairment being evaluated for Alzheimer's disease to identify patients with neurofibrillary tangle (NFT) pathology.
